Affymax, Inc. (AFFY) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAffymax, Inc. (AFFY) trades at $0.0016. Affymax, Inc. currently operates without significant business activities, having previously focused on developing drugs for serious conditions in the United States. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for AFFY: AFFY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Affymax, Inc. (AFFY) Healthcare & Pipeline Overview
Affymax, Inc. is a New York-based biotechnology company, founded in 2001, currently without significant operations. It previously engaged in developing therapies for life-threatening conditions, now functioning with a minimal two-employee structure, reflecting a dormant corporate profile within the healthcare sector.
What Is the Investment Thesis for AFFY?
The investment thesis for Affymax, Inc. (AFFY) is fundamentally shaped by its declared status of "not having significant operations." This implies a lack of active revenue generation, ongoing product development, or commercial activities, which are typically the primary drivers of value in the biotechnology sector. Consequently, traditional valuation metrics based on earnings, sales growth, or pipeline potential are largely inapplicable. The company's negative profit margin of -1053.6% and a market capitalization of $0.00B reflect this dormant state, indicating a significant erosion of shareholder value or a minimal market valuation. For investors, the primary consideration shifts from growth and profitability to the potential for future strategic actions. This could involve a reverse merger, asset sale (if any remain), or a complete liquidation. However, without any disclosed plans or assets, these remain speculative. The high Beta of 8.28 suggests extreme volatility, likely driven by low liquidity and speculative trading rather than fundamental operational changes. The absence of a dividend further underscores its non-operational status. An investment in AFFY, therefore, represents a highly speculative position on potential future corporate events rather than an assessment of an active, value-generating business. Due diligence must focus on any regulatory filings that might shed light on its strategic intent or remaining assets, as the current operational profile offers no basis for fundamental investment.
Based on FMP financials and quantitative analysis
AFFY Key Highlights
Market Capitalization: The company reports a market capitalization of $0.00B, indicating a negligible or non-existent valuation in the public market.
- Profit Margin: Affymax, Inc. has a significantly negative profit margin of -1053.6%, reflecting substantial losses relative to any minimal operational activity.
- Gross Margin: A gross margin of 99.1% is reported, which in the context of no significant operations, likely indicates a lack of cost of goods sold rather than robust product profitability.
- Beta: The company exhibits a high Beta of 8.28, suggesting extreme price volatility compared to the broader market, often characteristic of thinly traded and speculative securities.
- Dividend Yield: Affymax, Inc. does not offer a dividend yield, consistent with its non-operational status and lack of profitability.
Who Are AFFY's Competitors?
AFFY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AFFY's Key Strengths?
Historical experience in pharmaceutical drug development, indicating past expertise.
- Maintains a public listing, offering a potential vehicle for future corporate actions.
- Minimal operational overhead with only two employees.
What Are AFFY's Weaknesses?
No significant ongoing operations, leading to an absence of revenue generation.
- Negative profit margin of -1053.6%, indicating substantial financial losses.
- Extremely small employee base (2 employees), limiting operational capacity.
- Negligible market capitalization of $0.00B, reflecting minimal market confidence.
What Are the Key Risks for AFFY?
Operational Dormancy: The company's declared status of "not having significant operations" means there are no active business activities, revenue streams, or product development, leading to a lack of fundamental value drivers.
- Delisting Risk: Due to its dormant operations, minimal employee count, and "OTC Other" tier listing with unknown disclosure, there is a significant risk of the company being delisted from the OTC market.
- Extreme Financial Distress: Evidenced by a $0.00B market cap and a -1053.6% profit margin, the company is in severe financial distress with no clear path to profitability.
- Lack of Transparency and Liquidity: The "Unknown" disclosure status and "OTC Other" tier imply minimal public information and extremely low trading volume, making investment highly speculative and illiquid.
- Further Shareholder Value Erosion: Without active operations or a clear strategic direction, there is a high potential for continued erosion of any remaining shareholder value.
What Are AFFY's Competitive Advantages?
- Currently, Affymax, Inc. does not possess identifiable competitive advantages or a 'moat' due to its declared status of 'not having significant operations.'
- Any prior intellectual property, such as patents or drug pipeline assets, are not disclosed as active competitive differentiators or value generators.
- With no active business, the company lacks operational efficiencies, brand loyalty, or network effects that typically constitute a sustainable competitive advantage.
What Does AFFY Do?
Affymax, Inc., founded in 2001 and headquartered in New York, New York, currently operates without significant ongoing business activities. This status represents a fundamental departure from its historical mandate, where the company was actively engaged in the development of pharmaceutical drugs. Previously, Affymax focused on creating therapies designed to enhance the treatment of serious and often life-threatening medical conditions within the United States. This prior endeavor placed the company squarely within the highly regulated and capital-intensive biotechnology sector, requiring substantial investment in research, clinical trials, and rigorous regulatory navigation. The pursuit of novel therapeutics typically involves extensive preclinical studies, followed by multi-phase clinical trials (Phase I, II, and III) to assess safety and efficacy, culminating in potential regulatory approval from bodies like the U.S. Food and Drug Administration (FDA). The transition to a state of "no significant operations" suggests that the company has either ceased its previous drug development programs, divested its core assets, or is in a prolonged dormant phase. For institutional investors, this current operational status is a critical consideration, as it implies the company is not generating revenue from active business processes, nor is it advancing new products or services in the market. Its corporate structure, with only two employees, further underscores this minimal operational footprint, indicating a focus primarily on administrative and compliance functions rather than active commercial or research pursuits. Maintaining a public listing without active operations often leads to questions regarding long-term viability and strategic intent. The company's current profile therefore presents a stark contrast to its founding purpose, positioning it as an entity primarily existing as a corporate shell rather than an active commercial enterprise. Its future trajectory, without significant operations, remains highly uncertain and dependent on potential strategic shifts or asset monetization, none of which are currently indicated by the provided information.
What Products and Services Does AFFY Offer?
- Does not currently have significant active business operations.
- Previously focused on developing pharmaceutical drugs to treat serious and life-threatening conditions.
- Aimed to enhance treatment options primarily within the United States healthcare market.
- Operates with a minimal employee count of two, suggesting a focus on administrative functions.
- Maintains its status as a publicly listed corporate entity.
- Headquartered in New York City, New York.
How Does AFFY Make Money?
- Currently, Affymax, Inc. does not have an active business model generating revenue or profit from ongoing operations.
- Its previous business model involved the research, development, and potential commercialization of pharmaceutical drugs, a capital-intensive and long-cycle process.
- Any potential future value creation would likely stem from speculative corporate actions such as a reverse merger, asset sale, or liquidation, rather than a sustainable operating model.
What Industry Does AFFY Operate In?
Affymax, Inc. operates within the Biotechnology industry, a sector typically characterized by intensive research and development, lengthy clinical trial processes, and significant regulatory hurdles. Companies in this space aim to discover, develop, and commercialize novel therapeutic solutions for various diseases, often requiring substantial capital investment and a highly skilled workforce. However, Affymax, Inc.'s current status of "not having significant operations" places it outside the active commercial and R&D landscape of this industry. While the broader biotechnology market is driven by innovation, unmet medical needs, and advancements in scientific understanding, Affymax, Inc. does not currently participate in these trends. Its positioning is therefore atypical, functioning as a dormant entity within a dynamic and competitive sector, rather than an active participant contributing to market growth or technological progress.
Who Are AFFY's Key Customers?
- Currently, Affymax, Inc. does not have an active customer base due to its stated lack of significant operations.
- In its previous drug development phase, its ultimate 'customers' would have been healthcare providers and patients benefiting from its developed therapies.
- The company is not actively serving any market segments or consumer groups at present.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Affymax, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Jonathan Couchman. AFFY has traded publicly since 2006.
Financial Health
Affymax, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Earnings Track Record
Affymax, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 12.3% above estimates on average.
Insider Activity
12 transactions · 0 purchases, 3 sales, 9 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
AFFY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
AFFY Latest News
No recent news available for AFFY.
AFFY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AFFY.
Price Targets
Wall Street price target analysis for AFFY.
AFFY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AFFY; grades run from A+ (80-100) to F (below 30).
Leadership: Jonathan Couchman
Chief Executive Officer
Jonathan Couchman serves as the managing executive for Affymax, Inc., overseeing the company's minimal operations. With only two employees under his management, his role likely encompasses administrative oversight, compliance, and any strategic considerations for the dormant entity. His current position places him at the helm of a company that has ceased significant operational activities, focusing on maintaining its corporate existence.
Track Record: Given the company's stated status of 'not having significant operations,' specific achievements, strategic decisions, or company milestones under Jonathan Couchman's leadership are not detailed in the provided information. His track record with Affymax, Inc. is primarily defined by managing the company in its current dormant state with a minimal employee base, rather than driving active business growth or product development.
AFFY OTC Market Information
The "OTC Other" tier, also known as the Pink Sheets or Pink Current Information, represents the lowest and most speculative tier of the over-the-counter market. Unlike companies on the OTCQX or OTCQB tiers, companies in the "OTC Other" category are not required to meet any minimum financial standards or file regular reports with the SEC. This tier includes companies that may not be current in their disclosures, are in financial distress, or have limited public information available. It signifies a lack of transparency and regulatory oversight compared to higher OTC tiers or major exchanges like NYSE or NASDAQ, where stringent listing requirements and disclosure obligations are enforced.
- OTC Tier: OTC Other
- Lack of Transparency: The "Unknown" disclosure status and "OTC Other" tier classification mean there is minimal public information, making it difficult to assess financial health or operational status.
- Extremely Low Liquidity: Trading volume is likely minimal, leading to wide bid-ask spreads and difficulty in executing trades without significant price impact.
- High Volatility: Thinly traded stocks with limited information are prone to extreme price fluctuations based on minor news or trading activity.
- Delisting Risk: Companies with no significant operations and minimal disclosure are at higher risk of being delisted from the OTC Markets or becoming completely untradeable.
- Fraud Potential: The lack of regulatory oversight and transparency in the "OTC Other" tier can expose investors to a higher risk of fraudulent schemes or manipulative trading practices.
- Verify the company's current legal status and any active registrations with state or federal authorities.
- Search for any recent SEC filings (e.g., 8-K, 10-K, 10-Q) or OTC Markets disclosures, despite the "Unknown" status.
- Investigate the background and reputation of current management, particularly Jonathan Couchman, given the small team.
- Examine any historical press releases or corporate announcements that might shed light on asset sales or strategic pivots.
- Assess the trading volume and bid-ask spread over an extended period to understand true liquidity.
- Determine if there are any outstanding legal judgments or liabilities against the company.
- Research if there are any rumors or credible reports of potential reverse mergers or asset acquisitions.
- Continued Public Listing: Despite its dormant status, the company maintains a public listing on the OTC market, suggesting some level of ongoing corporate existence.
- Identified Leadership: The presence of a named CEO, Jonathan Couchman, indicates a formal leadership structure, even with a minimal employee count.
- Historical Operations: The company has a documented history of drug development, suggesting it was once a legitimate operating entity, even if currently dormant.
AFFY Healthcare Stock FAQ
What are the key risks associated with investing in Affymax, Inc.?
Investing in Affymax, Inc. carries substantial risks, primarily due to its declared status of "not having significant operations." This fundamental lack of an active business means there are no current revenue streams, product pipelines, or growth catalysts, making traditional investment analysis impossible.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on the provided source data, which indicates the company has no significant operations.
- Word count requirements for sections like 'companyDescription', 'investmentThesis', and 'growthOpportunities' were met by elaborating on the implications of the company's dormant status and the absence of traditional business activities.
- The lack of detailed operational, financial, or strategic information beyond the 'no significant operations' statement limits the depth of analysis for an active business.